Form 4: ADMA Biologics CEO Adam Grossman Reports Stock and Option Awards
SEC Form 4 Filing
Adam Grossman, CEO of ADMA Biologics, reports the acquisition of restricted stock units and stock options, along with existing holdings.
Summary
- Adam Grossman, the President and CEO of ADMA Biologics, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
- On February 26, 2024, Grossman acquired 557,728 restricted stock units (RSUs) that vest quarterly over four years.
- He also acquired options to purchase 870,950 shares of common stock at an exercise price of $5.40, vesting over four years.
- Following these transactions, Grossman directly owns 2,766,581 shares of common stock, including unvested RSUs and shares acquired through prior vesting.
- Grossman also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices and insider ownership transparency, which are generally viewed favorably.
Positives
- The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedules of the RSUs and options incentivize long-term performance and retention.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Comparison to Industry Standards
- Equity compensation packages, including RSUs and stock options, are common in the biotechnology industry to attract and retain top talent.
- Vesting schedules of four years are typical for such grants, aligning executive incentives with long-term company performance.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity compensation strategies for their executives.
Stakeholder Impact
- Shareholders gain insight into the CEO's stake in the company and alignment of interests.
- Employees may be indirectly affected by the CEO's incentives to drive company performance.
Key Dates
| Date | Description |
|---|---|
| 02/25/2021 | Grant date of 45,785 unvested RSUs. |
| 09/29/2021 | Grant date of 226,875 unvested Time-Based RSUs. |
| 03/07/2022 | Grant date of 225,000 unvested RSUs. |
| 12/31/2022 | Start date for vesting of Time-Based RSUs. |
| 03/06/2023 | Grant date of 573,695 RSUs. |
| 02/26/2024 | Date of transaction: Acquisition of 557,728 RSUs and options to purchase 870,950 shares. |
| 02/26/2034 | Expiration date of stock options. |
| 12/31/2024 | Full vesting date of Time-Based RSUs. |
| 02/28/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.